12:09 PM EST, 12/02/2024 (MT Newswires) -- (Updates with stock move in the headline and first paragraph.)

NovoCure's ( NVCR ) shares rose more than 41% in recent Monday trading after the company and Zai Lab ( ZLAB ) said that their phase 3 trial evaluating TTFields along with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma achieved its primary endpoint, demonstrating a "statistically significant" improvement in median overall survival.

NovoCure ( NVCR ) plans regulatory filings in the US, EU, Japan, and other major markets, while Zai Lab ( ZLAB ) plans to file for regulatory approval in China, the companies said.

Price: 28.83, Change: -0.02, Percent Change: -0.07